JP2020502157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502157A5 JP2020502157A5 JP2019532088A JP2019532088A JP2020502157A5 JP 2020502157 A5 JP2020502157 A5 JP 2020502157A5 JP 2019532088 A JP2019532088 A JP 2019532088A JP 2019532088 A JP2019532088 A JP 2019532088A JP 2020502157 A5 JP2020502157 A5 JP 2020502157A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- pharmaceutically acceptable
- cancer
- glioblastoma
- enoylpiperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000005017 glioblastoma Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 4
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims 4
- 208000032612 Glial tumor Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 4
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims 4
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 4
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims 4
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- -1 2 -cyclopropyl Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000007312 paraganglioma Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- JVTRZJXFAOQMRA-UHFFFAOYSA-N 1,3-oxazin-2-one Chemical compound O=C1N=CC=CO1 JVTRZJXFAOQMRA-UHFFFAOYSA-N 0.000 claims 1
- BASWGFWYCDZRSM-HXBUSHRASA-N 1-ethyl-7-[[(1S)-1-[4-[1-(4-prop-2-enoylpiperazin-1-yl)propyl]phenyl]ethyl]amino]-4H-pyrimido[4,5-d][1,3]oxazin-2-one Chemical compound CCC(N1CCN(CC1)C(=O)C=C)C1=CC=C(C=C1)[C@H](C)NC1=NC2=C(COC(=O)N2CC)C=N1 BASWGFWYCDZRSM-HXBUSHRASA-N 0.000 claims 1
- AFGYODUJVVOZAX-YADARESESA-N 7-[[(1S)-1-[4-[(1R)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one Chemical compound CCN1C(=O)OCc2cnc(N[C@@H](C)c3ccc(cc3)[C@@H](CC3CC3)N3CCN(CC3)C(=O)C=C)nc12 AFGYODUJVVOZAX-YADARESESA-N 0.000 claims 1
- AFGYODUJVVOZAX-CYFREDJKSA-N 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one Chemical compound CCN1C(=O)OCC2=C1N=C(N[C@@H](C)C1=CC=C(C=C1)[C@H](CC1CC1)N1CCN(CC1)C(=O)C=C)N=C2 AFGYODUJVVOZAX-CYFREDJKSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435283P | 2016-12-16 | 2016-12-16 | |
| US62/435,283 | 2016-12-16 | ||
| PCT/US2017/065246 WO2018111707A1 (en) | 2016-12-16 | 2017-12-08 | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502157A JP2020502157A (ja) | 2020-01-23 |
| JP2020502157A5 true JP2020502157A5 (enExample) | 2020-03-05 |
| JP6793836B2 JP6793836B2 (ja) | 2020-12-02 |
Family
ID=60888651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532088A Active JP6793836B2 (ja) | 2016-12-16 | 2017-12-08 | 変異体ｉｄｈ１およびｉｄｈ２阻害剤としての７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物 |
Country Status (37)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102209667B1 (ko) | 2014-09-19 | 2021-01-29 | 포르마 세라퓨틱스 인크. | 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체 |
| MX372964B (es) | 2014-09-19 | 2020-03-27 | Forma Therapeutics Inc | Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) |
| AU2015317321B2 (en) | 2014-09-19 | 2020-03-12 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| EP3201185B1 (en) | 2014-09-19 | 2018-11-21 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2016171755A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| JOP20190090B1 (ar) | 2016-10-24 | 2023-03-28 | Astrazeneca Ab | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| PH12019501328B1 (en) * | 2016-12-16 | 2023-05-12 | Lilly Co Eli | 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors |
| JP7291077B2 (ja) | 2016-12-16 | 2023-06-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｊａｋファミリーのキナーゼの低分子阻害物質 |
| EP3689873B1 (en) | 2017-01-30 | 2022-09-14 | Astrazeneca AB | Estrogen receptor modulators |
| US20210196701A1 (en) | 2018-05-16 | 2021-07-01 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| US11497743B2 (en) | 2018-05-16 | 2022-11-15 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11738018B2 (en) | 2018-05-16 | 2023-08-29 | FORMA Therapeuetics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| ES3033669T3 (en) | 2019-11-08 | 2025-08-06 | Nerviano Medical Sciences Srl | Gem-disubstituted heterocyclic compounds and their use as idh inhibitors |
| AU2021241470B2 (en) * | 2020-03-23 | 2023-12-14 | Board Of Regents, The University Of Texas System | Combination therapy with a mutant IDH inhibitor and a Bcl-2 inhibitor |
| ES2981250T3 (es) * | 2020-03-23 | 2024-10-08 | Lilly Co Eli | Terapia combinada con un inhibidor de IDH mutante |
| IL296094A (en) * | 2020-03-23 | 2022-11-01 | Lilly Co Eli | Method for treating idh1 inhibitor-resistant subjects |
| JP7712955B2 (ja) | 2020-04-24 | 2025-07-24 | アストラゼネカ・アクチエボラーグ | 癌の治療のための投薬レジメン |
| MX2022013258A (es) | 2020-04-24 | 2022-11-14 | Astrazeneca Ab | Formulaciones farmaceuticas. |
| CN115768775B (zh) * | 2020-06-28 | 2024-10-25 | 微境生物医药科技(上海)有限公司 | Idh突变体抑制剂及其用途 |
| JP2023534991A (ja) * | 2020-07-20 | 2023-08-15 | イーライ リリー アンド カンパニー | 変異型ｉｄｈ１阻害剤、デオキシアデノシン類似体、及び白金剤を用いた併用療法 |
| AU2022233254A1 (en) | 2021-03-11 | 2023-10-26 | Janssen Pharmaceutica Nv | Lorpucitinib for use in the treatment of jak mediated disorders |
| CN113588768B (zh) * | 2021-05-18 | 2022-07-05 | 国家卫生健康委科学技术研究所 | 一种以分子图像方式定量组织内内源性代谢物的质谱方法 |
| CN117460514A (zh) * | 2021-06-09 | 2024-01-26 | 伊莱利利公司 | 用于治疗idh抑制剂耐药的对象的方法 |
| US20240208978A1 (en) * | 2021-06-15 | 2024-06-27 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Idh mutant inhibitor and use thereof |
| CA3224704A1 (en) | 2021-08-13 | 2023-02-16 | David Andrew Coates | Solid forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2-enoylpiper azin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h- pyrimido[4,5-d] [1,3]oxazin-2-one |
| WO2023141087A1 (en) | 2022-01-19 | 2023-07-27 | Eli Lilly And Company | Combination therapy with a mutant idh inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012313888B2 (en) * | 2011-09-27 | 2016-03-31 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
| BR112015022483A2 (pt) * | 2013-03-14 | 2017-07-18 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
| WO2014147586A1 (en) * | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| WO2016171755A1 (en) * | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2016171715A1 (en) * | 2015-04-24 | 2016-10-27 | Halliburton Energy Services, Inc. | Methods of fabricating ceramic or intermetallic parts |
| JP6473270B2 (ja) * | 2015-07-27 | 2019-02-20 | イーライ リリー アンド カンパニー | ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用 |
| ES2814290T3 (es) * | 2016-06-06 | 2021-03-26 | Lilly Co Eli | Inhibidores de IDH1 mutante |
| PH12019501328B1 (en) * | 2016-12-16 | 2023-05-12 | Lilly Co Eli | 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors |
-
2017
- 2017-12-08 PH PH1/2019/501328A patent/PH12019501328B1/en unknown
- 2017-12-08 SI SI201730488T patent/SI3555105T1/sl unknown
- 2017-12-08 KR KR1020197016855A patent/KR102276022B1/ko active Active
- 2017-12-08 CA CA3045303A patent/CA3045303C/en active Active
- 2017-12-08 NZ NZ754115A patent/NZ754115A/en unknown
- 2017-12-08 WO PCT/US2017/065246 patent/WO2018111707A1/en not_active Ceased
- 2017-12-08 PT PT178228821T patent/PT3555105T/pt unknown
- 2017-12-08 MA MA47399A patent/MA47399B1/fr unknown
- 2017-12-08 JP JP2019532088A patent/JP6793836B2/ja active Active
- 2017-12-08 US US16/349,873 patent/US11001596B2/en active Active
- 2017-12-08 JO JOP/2019/0142A patent/JOP20190142B1/ar active
- 2017-12-08 PE PE2019001077A patent/PE20190977A1/es unknown
- 2017-12-08 EP EP20189241.1A patent/EP3763717B1/en active Active
- 2017-12-08 ES ES17822882T patent/ES2835281T3/es active Active
- 2017-12-08 MY MYPI2019003350A patent/MY197313A/en unknown
- 2017-12-08 EA EA201991161A patent/EA036112B1/ru not_active IP Right Cessation
- 2017-12-08 EP EP17822882.1A patent/EP3555105B1/en active Active
- 2017-12-08 TN TNP/2019/000158A patent/TN2019000158A1/en unknown
- 2017-12-08 HU HUE17822882A patent/HUE052067T2/hu unknown
- 2017-12-08 AU AU2017378060A patent/AU2017378060B2/en active Active
- 2017-12-08 HR HRP20201882TT patent/HRP20201882T1/hr unknown
- 2017-12-08 LT LTEP17822882.1T patent/LT3555105T/lt unknown
- 2017-12-08 MA MA053881A patent/MA53881A/fr unknown
- 2017-12-08 CN CN202210758386.7A patent/CN115109075B/zh active Active
- 2017-12-08 CR CR20190252A patent/CR20190252A/es unknown
- 2017-12-08 PL PL17822882T patent/PL3555105T3/pl unknown
- 2017-12-08 MD MDE20191188T patent/MD3555105T2/ro unknown
- 2017-12-08 MX MX2019006830A patent/MX385562B/es unknown
- 2017-12-08 CN CN201780078017.0A patent/CN110072867B/zh active Active
- 2017-12-08 UA UAA201905584A patent/UA123640C2/uk unknown
- 2017-12-08 DK DK17822882.1T patent/DK3555105T3/da active
- 2017-12-08 ES ES20189241T patent/ES2941631T3/es active Active
- 2017-12-08 RS RS20201429A patent/RS61108B1/sr unknown
-
2019
- 2019-05-17 ZA ZA2019/03125A patent/ZA201903125B/en unknown
- 2019-05-23 CO CONC2019/0005287A patent/CO2019005287A2/es unknown
- 2019-05-30 SA SA519401897A patent/SA519401897B1/ar unknown
- 2019-06-06 CL CL2019001551A patent/CL2019001551A1/es unknown
- 2019-06-11 IL IL267236A patent/IL267236B/en active IP Right Grant
- 2019-06-11 DO DO2019000163A patent/DOP2019000163A/es unknown
- 2019-06-14 EC ECSENADI201942682A patent/ECSP19042682A/es unknown
-
2020
- 2020-10-29 AU AU2020260493A patent/AU2020260493B2/en active Active
- 2020-11-25 CY CY20201101122T patent/CY1123577T1/el unknown
-
2021
- 2021-03-16 US US17/202,867 patent/US11629156B2/en active Active
- 2021-03-16 US US17/202,515 patent/US11649247B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201882T1 (hr) | SPOJEVI 7-FENILETILAMINO-4H-PIRIMIDO[4,5-d][1,3]OKSAZIN-2-ONA KAO INHIBITORI MUTANTNIH IDH1 I IDH2 | |
| JP2023036950A (ja) | 癌治療のための組み合わせ療法 | |
| JP2024133474A5 (enExample) | ||
| JP2023533464A5 (enExample) | ||
| CY1118232T1 (el) | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων | |
| WO2005044178A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
| HRP20220619T1 (hr) | Postupci za liječenje ar+ raka dojke | |
| JP2023541432A5 (enExample) | ||
| CY1107369T1 (el) | Μεθοδος για την παραγωγη μιας στερεας, χορηγουμενης απο του στοματος φαρμακευτικης συνθεσης με 5-χλωρο-ν({(5s)-2-οξο-3-[4-(3-οξο-4-μορφολινυλο)-φαινυλο]-1,3-οξαζολιδιν-5-υλο}-μεθυλο)-2-θειοφαινο-καρβοξαμιδιο | |
| BRPI0513843A (pt) | composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato | |
| HK1222297A1 (zh) | 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 | |
| WO2005046318A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | |
| TW200626159A (en) | Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor | |
| JP2008521928A5 (enExample) | ||
| JP2012512158A5 (enExample) | ||
| JP2010527981A5 (enExample) | ||
| JP2015524847A (ja) | 小細胞肺がんを治療するためのベンゾジアゼピン | |
| CY1113670T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης | |
| JP2014505107A5 (enExample) | ||
| JP2009515901A5 (enExample) | ||
| JP2020523356A5 (enExample) | ||
| JP2015527374A5 (enExample) | ||
| EA200601901A1 (ru) | Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием |